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ABSTRACT 
Purpose 
The aims of the study were to (i) quantify the sales of over-the-counter (OTC) ophthalmic 
chloramphenicol from all community pharmacies in Wales and investigate the impact on 
primary care prescriptions up to five years after reclassification and (ii) investigate the 
temporal relationship between items supplied OTC and on NHS primary care prescriptions. 
 
Methods 
Primary care prescription data (2004-10) and OTC sales data (2005-10) for ophthalmic 
chloramphenicol were obtained. The quantity sold OTC was calculated from pharmacy 
wholesale records and sales data from a large pharmacy multiple. Spearman’s rank 
correlation for prescription and OTC supplies of ophthalmic chloramphenicol was calculated 
for data from January 2008 to December 2010. 
 
Results 
OTC supply of chloramphenicol eye drops and ointment were both highest in 2007/08 and 
represented 68% (57,708/84,304) and 48% (22,875/47,192) of the corresponding prescription 
volume, respectively. There was a steady year-on-year increase in the combined supply of 
OTC ophthalmic chloramphenicol and that dispensed on prescription from 144,367 items in 
2004/05 to 210,589 in 2007/08 before stabilizing in 2008/09 and 2009/10. A significant 
positive correlation was observed between prescription items and OTC sales of 
chloramphenicol eye drops and ointment combined (r=0.7, p<0.001). 
 
Conclusion 
OTC availability increased the total quantity of ophthalmic chloramphenicol supplied in 
primary care compared to that seen prior to reclassification. Although growth in the sales of 
ophthalmic chloramphenicol OTC has stabilised and the supply pattern mirrors primary care 
prescribers, further work is required to investigate if use is appropriate and whether the 
publication of updated practice guidance has changed this. 
INTRODUCTION 
Regulatory background 
There are three categories for human medicines in the United Kingdom (UK), namely 
prescription-only medicines (POM), pharmacy-only (P) medicines and general sales list (GSL) 
medicines. POM medicines are only available on prescription, while P medicines can be sold 
from a pharmacy under the supervision of a pharmacist. In contrast, GSL medicines can be 
sold from most retail outlets.1,2 Over-the-counter (OTC) medicines is a collective term used to 
describe P and/or GSL medicines that can be purchased without a prescription although in 
this paper it is used exclusively to indicate supply from a community pharmacy. 
 
The main determinant of a medicine’s legal status is its safety, although factors such as side 
effects, monitoring requirements, route of administration, liability to misuse and risk to human 
health are also considered.2 When a medicine is ‘switched’ from one legal category to another 
this is termed reclassification. Reclassification from POM to P is associated with benefits for 
the patient3,4,5, government6,7,8, pharmacy profession9 and drug industry.10 Whether such 
reclassification is appropriate for an antimicrobial agent is unclear. 
 
Ophthalmic chloramphenicol  
Ophthalmic chloramphenicol was the first antibiotic available for purchase OTC in the UK and 
was indicated for the treatment of acute bacterial conjunctivitis. The eye drops were marketed 
in June 2005 and the ointment in July 2007, both as P medicines. The drug is routinely 
prescribed by primary care prescribers11 for suspected cases of infective conjunctivitis and is 
the recommended first-line treatment.12 Prior to OTC availability, community pharmacists 
were limited to selling antiseptic preparations such as propamidine and dibrompropamidine-
based products for ophthalmic infections.13 The proposal to make ophthalmic chloramphenicol 
available OTC was welcomed by various groups of healthcare professionals and the public 
following widespread consultation. At the time the benefit of improved and timely access to 
treatment outweighed the risks associated with wider accessibility14,15, although concerns 
regarding inappropriate over-supply, misdiagnosis by pharmacists and the emergence of 
increased bacterial resistance were raised.16 
 
Recent findings 
Since the launch of OTC ophthalmic chloramphenicol two main issues have come to light. 
First, pharmacy availability of ophthalmic chloramphenicol has been shown to have no impact 
on prescription supply for the same drug and, overall, there was a substantial increase in the 
supply of chloramphenicol in primary care in the first three years following reclassification.17,18 
Whether this situation remained the same beyond three years is unknown. Secondly, there is 
increasing clinical evidence that topical antibiotics are of limited benefit in infective 
conjunctivitis in primary care.19 Given that the condition is, in most cases, self-limiting20,21 and 
restricting use of antibiotics minimizes unnecessary treatment and emergence of resistance22, 
the current consensus in managing these patients is to adopt the practice of ‘no or delayed 
antibiotic’ supply23. Recent evidence suggests this may have impacted on the prescribing of 
ophthalmic chloramphenicol by GPs24 but whether supply OTC was affected remains unclear. 
 
The aims of the study, therefore, were to (i) quantify the sales of OTC ophthalmic 
chloramphenicol from all community pharmacies in Wales and investigate the impact on 
primary care prescriptions up to five years after reclassification and (ii) investigate the 
temporal relationship between items supplied OTC and on NHS primary care prescriptions. 
 
METHOD 
The study had an ecological design and involved a retrospective analysis of prescription data 
and OTC sales data for ophthalmic chloramphenicol supplied in Wales. 
 
Prescription data were extracted from CASPA.net (Comparative Analysis System for 
Prescribing Audit), an NHS Wales data store for primary care prescribing data. Data for all 
ophthalmic chloramphenicol preparations listed in the British National Formulary section 
11.3.113, prescribed and dispensed in Wales were extracted from CASPA.net for the period 
June 2004 to December 2010 (12 months before and 66 months after OTC ophthalmic 
chloramphenicol availability). 
 
OTC sales data were obtained from IMS Health and included four established proprietary 
brands of both chloramphenicol eye drops and ointment (Brochlor®, Golden Eye Antibiotic®, 
Galpharm Vision®, Optrex Infected Eyes®), together with one proprietary (Tubilux®) and one 
own-brand of eye drops. As at December 2010, there were two further proprietary brands of 
chloramphenicol eye drops available as P medicines in the UK 25 but data for these products 
were unavailable and thus not included in the analysis. Ophthalmic chloramphenicol 
preparations licensed as POMs, such as Minims eye drops, were excluded from the OTC 
sales analysis. The OTC sales data obtained were available from June 2005 to December 
2010 (66 months) and represented the supply of ophthalmic chloramphenicol preparations 
from wholesalers into 614/708 (87%) NHS-contracted community pharmacies in Wales. Data 
for the remaining 94 NHS-contracted pharmacies and eight pharmacies without NHS contract 
were obtained direct from the pharmacy chain concerned (Company A) for the period January 
2008 to December 2010 (36 months). OTC sales of chloramphenicol eye drops from 
Company A between June 2005 and December 2007 (30 months) and ointment between July 
and December 2007 (6 months) were estimated using linear regression. The line of best fit 
generated from the model was extrapolated backwards based on available cumulative sales 
data. The OTC sales from Company A (estimated and actual) were combined with IMS Health 
sales data to give the total quantity of OTC ophthalmic chloramphenicol sold in Wales from 
June 2005 to December 2010. 
  
Prescription and OTC supply 
The total number of items supplied on prescription or sold OTC are presented as the 12-
month totals for the eye drops, from June to May, and for the ointment, from July to June, to 
allow the comparison before and after their respective availability OTC. Correlation coefficient 
(r) for prescription items supplied and OTC sales of combined chloramphenicol eye drops and 
ointment was calculated using Spearman’s rank correlation, based on actual prescribing and 
OTC sales data between January 2008 and December 2010. 
 
All data analysis and statistics were performed using PASW version 18 (SPSS Inc., Chicago, 
IL, USA). 
 
RESULTS 
The linear regression model generated cumulative sales equations for eye drops (R2=0.998, 
P<0.0001) and eye ointment (R2=0.995, P<0.0001) for Company A and estimated cumulative 
sales for the respective periods when no data was available (data not shown). The total 
cumulative quantities of ophthalmic chloramphenicol sold OTC (IMS Health + Company A 
[actual and estimated OTC sales]) are shown in Figure 1. 
 
The supply of chloramphenicol eye drops from 2004/05 to 2009/10 is shown in Figure 2. It 
showed there was a steady increase in overall use of ophthalmic drops, prescribed and sold, 
from 2004/05 (86,916) to a peak in 2007/08 (142,013) before this plateaued in 2008/09 
(134,220) and 2009/10 (133,942). The supply of OTC eye drops was at its peak in 2007/08, 
equivalent to 68% (57,708/84,305) of the respective number of items supplied on prescription. 
The largest year-on-year reduction in supply of prescription eye drops occurred in 2005/06 (-
7%, 6,072/86,912), which corresponded to the period when OTC chloramphenicol eye drops 
were launched (June 2005). Subsequent changes were -3% (2,536/80,844), +7% 
(5,997/78,308), 0% (1/84,305) and 0.3% (282/84,306) from 2006/07 to 2009/10, respectively. 
 
Ophthalmic chloramphenicol eye ointment was reclassified in 2007 and the subsequent 
quantities supplied are shown in Figure 3. The largest reduction of prescribed ointment 
compared with the previous year was seen in 2007/08 (-13%, 7,218/54,410) and coincided 
with the launch of OTC eye ointment in July 2007. During this period (2007/08), OTC sales of 
ointment were 48% (22,875/47,192) of their respective prescription volume. Subsequent sales 
of OTC ointment fell by 29% (6,563/22,875) in 2008/09 to 16,312 packs, equivalent to 31% 
(16,312/52,811) of the respective prescription volume and in 2009/10 OTC sales was 33% 
(17,061/51,410) of the respective prescription volume. The overall impact of OTC 
chloramphenicol ointment availability in 2007/08 was to increase its total supply in Wales by 
29% (15,657/54,410) compared to the previous year, which then remained consistently higher 
than the quantities supplied in any other 12-month period before July 2007 when the ointment 
were only available on prescription. 
 
A summary of the combined quantities of eye drops and ointment sold OTC or supplied on 
prescription is shown in Figure 4. 
 
In the period January 2008 to December 2010, a marked seasonal variation for eye drops 
supplied on both prescription and sold OTC was observed, with peaks occurring between 
December to March and nadirs between August to October each year. In comparison, the 
supply of the ointment showed no discernable seasonal variation (Figure 5). Spearman’s rank 
correlation revealed a significant and positive correlation between prescriptions and OTC 
sales of chloramphenicol eye drops and ointment combined (r=0.7, p<0.001).  
 
DISCUSSION 
The pharmacy sales data presented in this study are the first and the most comprehensive 
dataset studied to date and include data from all NHS-contracted community pharmacies in 
Wales. The results demonstrate that the availability of ophthalmic chloramphenicol OTC has 
contributed to an increase in the supply of chloramphenicol greater than previously 
identified.18 Supplies of OTC chloramphenicol eye drops increased from 2005 to 2007 but 
have subsequently remained stable. Similarly, the availability of OTC eye ointment increased 
overall use in primary care. It would appear that despite the relatively large quantity of 
ophthalmic chloramphenicol being sold OTC, it has had little or no impact on prescription 
supply some five years after it was reclassified to a P medicine. As a consequence there has 
been no cost saving on drug expenditure for the NHS as was initially expected.26 When the 
temporal relationship between OTC sales of ophthalmic chloramphenicol and items 
dispensed on prescription was explored, it was found that there was a positive relationship. 
This may, in part, suggest community pharmacists and primary care prescribers were 
responding to similar presenting symptoms but whether or not prescribing and/or OTC sales 
were appropriate is unclear. 
 
Study Limitations 
Primary care prescribing data was comprehensive, and extracted from an established and 
routinely used database that included details of NHS prescriptions dispensed by every 
community pharmacy in primary care in Wales. The OTC sales data were obtained from two 
sources: IMS Health and a pharmacy chain (Company A). Previous research noted that sales 
data collected by IMS Health only included 87% of all community pharmacies in Wales18 and, 
as such, sales would underestimate the actual volume sold. In the present study, sales figures 
from Company A were obtained and complemented the IMS Health dataset. It should also be 
noted that two other branded products came to OTC market during the study. While data for 
these two products was not captured in the IMS Health dataset there appeared to be no 
impact on sales of the products monitored. Moreover we could identify the total amount of 
ophthalmic chloramphenicol prescribed and sold throughout the period of the study and this 
indicated sales of these new brands were negligible. 
 
Unlike the IMS Health data, which were available for the entire post-reclassification period, 
sales data from Company A were only available from 2008 to 2010, and therefore the 
quantities sold during the first three years following OTC availability had to be estimated. It 
was possible that the sales pattern during the early months of a new product could have been 
markedly different. However, the available sales trend data from IMS Health for the other 
614/708 community pharmacies in Wales indicated this was not an issue. 
 
An important difference between the pharmacy sales data utilized in the present study is that 
while data from Company A represented transactions between pharmacy and customers, IMS 
Health data reported supplies from wholesalers to pharmacies. As with previous studies that 
have employed IMS Health sales data18,24, the latter was identified to be a good proxy for 
pharmacy-to-customer sales. This relationship is likely to hold for chloramphenicol eye drops 
as they need to be stored in a fridge, where space is usually at a premium, and bulk advance 
purchases unlikely. Advanced ordering in anticipation of increased demand associated with, 
for example, an upcoming advertising campaign, and/or bulk-purchase discount offers would 
have distorted sales figures but we have no evidence this was the case over the study period 
monitored. 
 
The present study was limited by its ecological nature, and consequently we were unable to 
identify factors that caused the increased and sustained supply of ophthalmic 
chloramphenicol OTC. It was likely that the removal of barriers such as the need to make a 
GP appointment, improved access and cost of travelling to and from doctor’s surgery 
provided sufficient incentive for people to practice self-care3, even if individuals had to 
purchase the treatment themselves in a country with no co-payment prescription levy. Sales 
could have been stimulated by promotional activities and, as a result, improved the public’s 
awareness of conjunctivitis and product availability. Although there was a temporal 
relationship between OTC sales and items supplied on prescription, suggesting that patients 
with similar presentations were turning up at both community pharmacies and GP surgeries 
and were supplied ophthalmic chloramphenicol. This result needs to be interpreted with 
caution as it only serves to demonstrate an association between the two variables rather than 
providing an explanation for them. To date there has been no published data that has 
evaluated the appropriateness of prescribing or OTC supply of ophthalmic chloramphenicol in 
primary care, even if such criteria could be defined. 
 
Comparison with literature 
Contrary to the trend of reduced prescribing for ophthalmic chloramphenicol reported in 
England26, the number of prescribed items for both eye drops and ointment in Wales 
remained similar despite the high volume of OTC sales following reclassification. This 
observation could have been influenced by the abolition of the NHS prescription charge in 
Wales (April 2007), which may have encouraged patients to obtain a free prescription from 
their doctor. In England where prescription co-payment was still in place, it was cheaper for 
patients who paid the prescription charge to purchase ophthalmic chloramphenicol OTC given 
the average price of eye drops and ointment were £4.72 and £5.24 respectively, whereas the 
cost of a prescription item was £6.50 in 2005 and £7.40 in 2011. Our data demonstrated that 
during the 12-month period (June 2007 to May 2008) after the abolition of prescription charge 
in Wales, there was a small but distinguishable increase in eye drops dispensed on 
prescription, which is consistent with the observation made by others of an increase in 
prescription items following abolition of the co-payment charge.27 This was not observed with 
the ointment over the same period but is probably because the market had not matured or 
stabilized. It has been suggested that the decrease in the number of items prescribed for 
chloramphenicol eye drops and ointment in England was due to a change in the management 
of conjunctivitis from empirical prescribing to no or delayed prescribing.24 Whether or not 
prescribers in Wales adopted this approach is unknown. Moreover, changes in prescriber 
preference, such as switching from one topical ophthalmic antibiotic to another may have 
confounded the picture. 
 
Walker and Hinchliffe17 reported a year-on-year increase in OTC sales of ophthalmic 
chloramphenicol eye drops in Wales during the three-year period post-reclassification. 
Likewise, Davis et al24 reported a similar trend for England from 2005 to 2007. The present 
study demonstrates that sales of OTC chloramphenicol eye drops eventually stabilized four 
years post-reclassification. The seasonal variation observed for chloramphenicol eye drops 
sold OTC in Wales was consistent with the incidences of bacterial conjunctivitis reported by 
Block et al28, with peaks in the winter months of December to February and a low incidence in 
the summer months of June to August. It was noted that the ophthalmic ointment whether 
prescribed or sold OTC lacked the same seasonal feature. The reasons for this are unclear 
but probably related to the smaller quantity of ointment supplied and the preference of 
patients for the drops to avoid prolonged periods of blurred vision associated with the use of 
the ointment. 
 
IMPLICATIONS 
When ophthalmic chloramphenicol was reclassified in the UK, concerns were raised about the 
possibility of misdiagnosis16 and the risk of bacterial resistance29 due to inappropriate OTC 
supply. Over the five-year period following OTC availability, sales of ophthalmic 
chloramphenicol grew substantially before appearing to stabilize. Their apparent lack of 
impact on prescription use meant that there was no saving to the NHS drug budget nor a 
reduction to GP workloads. In view of the emerging evidence that support the practice of ‘no 
or delayed antibiotic’ in managing most primary care cases of acute conjunctivitis21,22,29,31,32, 
the updated prescribing guidance for OTC ophthalmic chloramphenicol issued by the Royal 
Pharmaceutical Society was imperative and befitting.33 Further monitoring is needed to 
determine whether pharmacists have subsequently embraced non-medicinal management 
such as eye bathing and postponing immediate antibiotic supply for acute bacterial 
conjunctivitis. It is recognised that the conventional signs and symptoms pharmacists’ rely on 
to distinguish bacterial from viral conjunctivitis33 are diagnostically non-informative.34 It is not 
improbable that some of the increase in OTC ophthalmic chloramphenicol sales has arisen 
because of misdiagnosis and therefore reflects inappropriate use as some have recently 
suggested35. Further, it is not known from sales data to what extent, if any, medicines counter 
assistants (MCAs) have been involved in any of the OTC supplies. Further research on this 
matter would be helpful as community pharmacists for many years have delegated some 
responsibility on OTC medicine sales to MCAs via medicines sales protocols36, although more 
recently it has been reported that that MCAs do not always comply with guidelines when 
dealing with OTC consultations.37 
 
CONCLUSION 
Over the five-year study period, there was an increase in overall supply of ophthalmic 
chloramphenicol following availability from community pharmacies without prescription. The 
initial year-on-year increase in overall supply reported by others17,24 appears to have 
stabilized four years post-reclassification while having little impact on prescription items over 
the entire study period. Despite a temporal relationship between OTC ophthalmic 
chloramphenicol supply and items dispensed on prescription, the appropriateness of supplies 
from community pharmacies remains unknown. The benefits and risks of having ophthalmic 
chloramphenicol available OTC and the impact of updated practice guidance on its 
prescribing OTC need to be studied further to better understand its current, high level of use. 
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